SES Selects Arianespace to Launch EAGLE-1 Satellite for Europe’s Quantum Cryptography
9.11.2022 10:50:00 EET | Business Wire | Press release
The EAGLE-1 satellite, which will support the end-to-end secure Quantum Key Distribution (QKD) system for Europe, will be launched for SES by Arianespace on a Vega C rocket from French Guiana as early as Q4 2024. The satellite will be placed into Low Earth Orbit (LEO). The EAGLE-1 project comprising satellite and ground infrastructure, is developed by SES and its consortium of 20 European partners, with the European Space Agency (ESA) and the European Commission support.
Under the recently-signed agreement with ESA, SES and its partners will design, develop, launch and operate a satellite-based end-to-end QKD system for the purpose of testing and validating space-based secure transmission of cryptographic keys. The first European sovereign space-based QKD system will include the dedicated low earth orbit (LEO) EAGLE-1 satellite and state-of-the-art QKD operations centre in Luxembourg. In the scope of EuroQCI, the EAGLE-1 satellite will enable early access, validation, and integration of space-based QKD for EU Member States.
“Building the EAGLE-1 end-to-end system for secure data transmission and validating the long-distance Quantum Key Distribution technology is an innovative project that will benefit the EU Member States,” said Ruy Pinto, Chief Technology Officer at SES. “We have been working with Arianespace for decades to deliver our satellites into space and are delighted for them to be onboard to launch the EAGLE-1 satellite into orbit.”
“We are delighted and honored by this renewed mark of confidence from the leading global content connectivity service provider SES,” noted Marino Fragnito, Director of Arianespace’s Vega business unit. “Over the last 38 years, Arianespace has carried out 42 launches for its longstanding partner, and Vega C will now continue this successful track record. It is a great honor for us to support our customer’s ambitions and to be part of this mission that aims at implementing Europe’s satellite-enabled cybersecurity technology.”
Following the launch, the EAGLE-1 satellite will complete three years of in-orbit mission supported by the European Commission. During this operational phase, the satellite will allow European Union governments and institutions, as well as critical business sectors, early access to long-distance QKD that would path the way towards an EU constellation enabling ultra-secure data transmissions.
The EAGLE-1 project is co-funded by the ESA contribution of Germany, Luxembourg, Austria, Italy, the Netherlands, Switzerland, Belgium, and the Czech Republic under ARTES, as well as the European Commission through Horizon Europe.
Vega C, the new European light launcher successfully passed its inaugural flight on July 13 and now enters its operational phase under the responsibility of Arianespace. With this contract, Vega C backlog includes over 40 satellites contracts.
Vega C development program has been managed by ESA with 12 Member States of the Agency. Avio Spa (Colleferro, Italy) is the industrial prime of the Vega launch system. Vega C has been upgraded with more powerful first and second stage Solid Rocket Motors and with a larger fairing, which significantly increases payload mass and double allowable volume as compared to Vega. The launcher also better meets the specific needs of small spacecrafts, thanks to its improved SSMS dispenser and to its AVUM+ that allows seven re-ignitions instead of five. Vega C can thus deliver to three different separation orbits for its multiple payloads within the same mission, instead of the two previously possible with Vega.
For more information, visit the EAGLE-1 Newsroom
Follow SES on:
Twitter | Facebook | YouTube | LinkedIn | Instagram
Follow Arianespace on:
Twitter | YouTube | LinkedIn | Instagram
About ESA
The European Space Agency (ESA) is Europe’s gateway to space. ESA is an intergovernmental organisation, created in 1975, with the mission to shape the development of Europe’s space capability and ensure that investment in space delivers benefits to the citizens of Europe and the world. For more information see www.esa.int
The Telecommunications and Integrated Applications Directorate (TIA) supports innovation to boost the competitiveness of European industry in the global space market. This involves a wide range of activities, from space-based technology, systems, products for telecommunications development to the down-to-Earth application of space-based services. It also calls for engagement with a wide range of industrial, academic, and institutional partners. For more information, please visit our website: https://artes.esa.int/
About SES
SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries ~8,000 channels and has an unparalleled reach of 366 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com.
About Arianespace
Arianespace uses Space to make life better on Earth by providing launch services for all types of satellites into all orbits. It has orbited over 1,100 satellites since 1980. Arianespace is responsible for operating the new-generation Ariane 6 and Vega C launchers, developed by ESA, with respectively ArianeGroup and Avio as industrial primes. Arianespace is headquartered in Evry, near Paris, and has a technical facility at the Guiana Space Center in French Guiana, plus local offices in Washington, D.C., Tokyo and Singapore. Arianespace is a subsidiary of ArianeGroup, which holds 74% of its share capital, with the balance held by 15 other shareholders from the Ariane and Vega European launcher industry, and ESA and Cnes as censors.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221108006349/en/
Contact information
For further information:
Suzanne Ong
External Communications, SES
Tel. +352 710 725 500
suzanne.ong@ses.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 17:00:00 EEST | Press release
PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 16:53:00 EEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release
Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release
Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
